Davis et al., 1999 - Google Patents
Transgenic mice as a source of fully human antibodies for the treatment of cancerDavis et al., 1999
- Document ID
- 18403655277882049493
- Author
- Davis C
- Gallo M
- Corvalan J
- Publication year
- Publication venue
- Cancer and Metastasis Reviews
External Links
Snippet
The last two years have seen a renaissance of monoclonal antibodies for the treatment of disease. Of the eight antibodies currently approved for human therapy, two are for the treatment of cancer. In large part, the revival of antibodies has been driven by technology …
- 102000004965 antibodies 0 title abstract description 85
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davis et al. | Transgenic mice as a source of fully human antibodies for the treatment of cancer | |
| Wang et al. | Development of therapeutic antibodies for the treatment of diseases | |
| CN107151269B (en) | PDL-1 antibody, pharmaceutical composition and application thereof | |
| Vaughan et al. | Human antibodies by design | |
| EP2686348B1 (en) | Bi- and monospecific, asymmetric antibodies and methods of generating the same | |
| JP3803790B2 (en) | Novel diabody-type bispecific antibody | |
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| Roque-Navarro et al. | Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method | |
| JP2017512815A (en) | Modified J chain | |
| CN114502591B (en) | Antibodies targeting BCMA, bispecific antibodies and uses thereof | |
| US20230338565A1 (en) | Antibody drug conjugate, preparation method therefor and use thereof | |
| CN1822857A (en) | De-immunized anti-CD3 antibody | |
| RU2007145419A (en) | MONOCLONAL HUMAN ANTIBODIES TO PROGRAMMABLE DEATH PROTEIN 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES INDEPENDENTLY OR IN COMBINATION WITH OTHER IMPORTANCE | |
| JP2010504743A5 (en) | ||
| WO2017143840A1 (en) | Method for expressing and preparing polyvalent multi-specific antibody and immune hybrid protein | |
| CN110337448A (en) | Use the immunotherapy of the antibody combined with programmed death ligand 1 (PD-L1) | |
| JP2022530301A (en) | CD3 antigen-binding fragment and its use | |
| Raum et al. | Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens | |
| WO2001031065A1 (en) | Humanization of non-human, mammalian antibodies | |
| Yagami et al. | Monoclonal antibodies based on hybridoma technology | |
| JP2024510811A (en) | UPAR antibody and its fusion protein | |
| JP2021528973A (en) | Anti-STEAP1 antigen-binding protein | |
| CN115715297A (en) | anti-FLT 3 antibodies and compositions | |
| Penichet et al. | Design and engineering human forms of monoclonal antibodies | |
| Nicolaides et al. | Monoclonal antibodies: a morphing landscape for therapeutics |